Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Elevated lipoprotein(a)

Lipoprotein(a), abbreviated Lp(a), is a lipoprotein particle consisting of an LDL-like component containing apoB100, covalently linked to apolipoprotein(a). Its concentration is largely genetically determined and represents a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic stenosis. An elevated level may be present even when LDL cholesterol, triglycerides, body weight, and lifestyle appear favorable.

Elevated Lp(a) identifies a biological exposure; it does not, by itself, demonstrate coronary or valvular stenosis. Risk increases continuously with concentration and also depends on other factors. Thresholds used in clinical documents make assessment operational, but they do not divide people into two groups in which risk is, respectively, absent and inevitable. Identification requires a specific assay: a standard lipid profile cannot reliably determine the level.

Concentrations considered elevated occur in a substantial proportion of the population, often estimated at approximately 20% using some of the most commonly adopted thresholds. Distribution, assay method, and population affect the estimate. Lp(a) tends to be higher in some ancestry groups, but individual assessment must rely on measurement and overall risk, without inferring the result from geographic origin. Elevation may account for some of the familial clustering of premature events that is not readily explained by conventional risk factors.

Genetics, structure, and pathogenesis

Apolipoprotein(a) is synthesized mainly in the liver and is encoded by the LPA gene. It contains structural domains called kringles, with a variable number of kringle IV type 2 repeats. This variation produces isoforms of different sizes and contributes to the large differences in concentration between individuals. In general, smaller isoforms are associated with higher levels, but the relationship is not perfect, and other variants regulate production and secretion.

Hereditary determination is very strong, with contributions from both alleles and considerable variation within families. However, it is incorrect to describe every high value as a dominantly inherited monogenic disorder with a simple penetrance threshold. The measured concentration reflects the combined effects of structural and regulatory variants, as well as clinical modifiers. Plasma measurement is generally more useful than LPA genotyping for routine risk assessment.

The particle contains an apoB100 component and can contribute to cholesterol delivery into the arterial wall. Apolipoprotein(a) confers properties that distinguish Lp(a) from conventional LDL. In particular, Lp(a) is an important carrier of oxidized phospholipids, associated with endothelial activation, monocyte recruitment, and inflammatory responses. Risk is therefore not adequately characterized by considering only the cholesterol carried by the particle.

The relationship with atherosclerosis is supported by prospective and genetic studies: variants associated with higher levels are accompanied by greater coronary risk, whereas variants that reduce production provide evidence consistent with causality. Mendelian randomization studies primarily describe differences in lifetime exposure; they do not automatically predict the magnitude of benefit from treatment started after decades of disease.

In the aortic valve, oxidized lipids and mediators carried by the particle may promote inflammation and osteogenic cellular programs. LPA genetics are associated with aortic valve calcification and stenosis, strengthening the causal link. However, initial deposition and progression in an already calcified valve are not therapeutically equivalent processes: demonstrating a causal association does not establish that lowering Lp(a) halts advanced stenosis.

The structural similarity between apo(a) and plasminogen has supported hypotheses of interference with fibrinolysis. Experimental data exist on proatherothrombotic mechanisms, but these should not automatically be interpreted as a diagnosis of venous thrombophilia. The strongest evidence concerns atherosclerotic disease and aortic stenosis; an elevated level alone is not an indication for anticoagulation or indiscriminate investigation for venous thrombosis.

Concentration depends mainly on hepatic production, whereas clearance involves pathways that are not fully understood. The kidneys and kidney disorders can modify Lp(a) metabolism; nephrotic syndrome and kidney failure can raise levels. Inflammation, pregnancy, hormonal conditions, and liver diseases may influence the result. Genetic predominance therefore does not imply absolute immutability at every clinical stage.

Interaction with LDL and other factors is crucial to absolute risk. The same Lp(a) concentration may have different prognostic implications in a young person without other risk factors and in someone who has already had a myocardial infarction, smokes, or has diabetes. Lowering LDL does not eliminate the component attributable to Lp(a), but it reduces a concurrent causal exposure and can provide a substantial benefit. Residual risk does not mean that available preventive measures are ineffective.

Clinical manifestations and settings that raise suspicion

Elevated Lp(a) is itself asymptomatic and has no pathognomonic physical finding. It does not cause a specific sensation of “thick” blood and cannot be identified from nonspecific symptoms. Any clinical manifestations belong to associated disease: angina, myocardial infarction, peripheral arterial disease, certain cerebrovascular events, or aortic stenosis. Their presence requires an independent diagnostic evaluation, not simply repeat measurement of the biomarker.

A family history of premature disease, events without marked hypercholesterolemia, or recurrent events despite good LDL control make measurement particularly informative. However, testing should not be restricted exclusively to these situations: contemporary consensus statements and guidelines support measuring Lp(a) at least once in adulthood. The aim is to identify an inherited determinant before it is discovered only after a clinical event.

History taking covers personal and family events, lipid levels, treatments, kidney disease, and conditions present at the time of blood sampling. In a patient with familial hypercholesterolemia (FH), elevated Lp(a) adds prognostic information and may contribute to a more severe phenotype. In aortic stenosis, age, echocardiographic severity, and symptoms remain the factors guiding valvular decisions, regardless of the assay result.

The physical examination looks for signs of cardiovascular disease, such as murmurs compatible with valvular disease or abnormal pulses, and assesses concurrent risk factors. A systolic murmur does not establish aortic stenosis caused by Lp(a); it must be characterized using appropriate investigations. Similarly, prominent tendon xanthomas warrant consideration of an associated dyslipidemia, because they are not a specific sign of isolated Lp(a) elevation.

Measurement, units, and interpretation

Measurement can be performed without fasting in most settings. An assay sufficiently independent of isoform size and appropriately calibrated is preferred. The report must clearly specify the unit: mg/dL expresses mass concentration, whereas nmol/L expresses the molar concentration of particles. The substantial variation in apo(a) size makes these two measurements conceptually different.

There is no reliable universal conversion factor between mg/dL and nmol/L. Systematically multiplying by 2 or 2.5 can create an illusion of precision and incorrectly change the risk category. Pairs of thresholds reported in clinical documents are operational reference values in their respective measurement systems, not formulas for converting an individual's result. When comparing successive tests, the assay and unit should be known and, if possible, the same laboratory should be used.

The 2022 EAS consensus statement and the 2024 NLA update describe a lower-risk range below 30 mg/dL or 75 nmol/L, an intermediate range between 30 and 50 mg/dL or between 75 and 125 nmol/L, and an elevated value from 50 mg/dL or 125 nmol/L. The 2025 ESC/EAS update instead uses a reference above 50 mg/dL or approximately 105 nmol/L as a risk modifier. Differences between molar thresholds should not be resolved through an improvised mathematical conversion: the reference used must be stated, while maintaining a continuous interpretation of risk.

Extremely high concentrations, for example around 180 mg/dL or higher, may be associated with a lifetime risk comparable to that of untreated heterozygous FH in some epidemiological assessments. This does not mean that the patient has FH or that the two mechanisms are identical. The comparison helps convey the importance of exposure, not replace a genetic diagnosis or predict an inevitable event.

One measurement in adulthood is often sufficient to identify the usual level, but repeat testing may be useful when results are close to a decision threshold, during acute conditions, with renal or hormonal changes, analytical uncertainty, or treatment that acts on the particle. Measuring a stable level every few months without therapeutic consequences does not necessarily add information. In children, concentration may change during development, and the approach should be tailored to family history and the reason for testing.

Lp(a)-cholesterol is included in most conventional LDL-C measurements. Very high Lp(a) may therefore contribute to an LDL-C level that appears resistant to therapies that do not substantially lower the particle. Routinely subtracting 30% of Lp(a) mass from LDL-C is not accurate for every individual, because cholesterol content varies. ApoB also includes the Lp(a) component but does not replace its specific measurement.

LPA genetic testing is not required for routine management of an elevated result. The assay directly reflects particle concentration and allows family assessment. Determining isoform sizes or specific variants remains a specialist or research tool, useful for defined questions. A commercial genetic test must not be used to rule out elevated Lp(a) when the plasma level has not been measured.

Risk assessment and further investigations

The result is integrated with baseline cardiovascular risk. In primary prevention, it may strengthen the case for intervention when the decision about LDL management was uncertain; in secondary prevention, it indicates a residual component that reinforces comprehensive risk-factor control. Adding a fixed percentage to the score from any model without a methodology validated for that tool is not appropriate.

Family assessment through measurement in first-degree relatives may identify other exposed individuals, especially when the level is very high or premature events have occurred. Not all relatives should be assumed to have the same concentration. In minors, testing is selective and takes into account FH, a family history of elevated Lp(a) or premature disease, and particular clinical settings; interpretation requires pediatric expertise and is not equivalent to indiscriminate screening with genetic panels.

Coronary artery calcium scoring or other measures of plaque may be useful in selected adults when the results would change a preventive decision. A score of zero reduces the likelihood of detectable significant calcified disease and can inform short-term risk, but does not negate future genetic exposure or exclude noncalcified plaque. Performing invasive coronary angiography or coronary CT angiography in every asymptomatic person with elevated Lp(a) is not justified.

Echocardiography is indicated when murmurs, symptoms, or other findings suggest valvular disease. Aortic stenosis cannot be inferred from Lp(a) alone, and the biomarker does not, by itself, determine follow-up intervals for a normal valve. When stenosis is documented, surveillance and intervention follow severity, symptoms, ventricular function, and valvular criteria. Lp(a) helps explain risk without replacing assessment of the lesion.

Investigation of modifying conditions should be proportionate to the context: kidney function, proteinuria, thyroid status, liver disease, and acute illness can help explain an unexpected result. Identifying a secondary component does not necessarily eliminate the hereditary component. It is useful to retain the value, assay method, and circumstances of sampling to avoid contradictory interpretations years later.

Treatment and limitations of the evidence

The primary strategy is to lower absolute risk by addressing exposures for which effective interventions are available: LDL and other apoB-containing particles, blood pressure, smoking, diabetes, and physical inactivity. Diet and physical activity have little effect on the inherited Lp(a) concentration but remain clinically beneficial. Explaining this distinction prevents patients from interpreting a lack of biomarker reduction as evidence that a healthy lifestyle is pointless.

Statins do not directly target Lp(a) and may leave its concentration unchanged or raise it slightly. This is not, in itself, a reason to discontinue them when indicated, because LDL reduction and prevention of events remain beneficial. Ezetimibe and bempedoic acid are selected for LDL control according to risk and tolerability, without promising a meaningful specific reduction in Lp(a). Lipid targets depend on the clinical risk category, not on one identical LDL value for everyone with elevated Lp(a).

Anti-PCSK9 antibodies also lower Lp(a), by a moderate amount on average, in addition to markedly reducing LDL. Analyses from FOURIER and other studies demonstrate the prognostic significance of Lp(a) and substantial benefit in exposed patients, but do not definitively separate the contribution of Lp(a) lowering from that of LDL lowering. They should therefore not be presented as stand-alone proof that any selective reduction in Lp(a) prevents events, nor as automatically indicated solely because the biomarker is high.

Lipoprotein apheresis can remove Lp(a) and LDL and may be considered in selected patients with progressive disease despite optimal treatment, according to specialist and national criteria. The immediate reduction is followed by a rebound, so the post-procedure level does not represent average exposure. Evidence on clinical events comes largely from observational studies, which are vulnerable to confounding and concurrent changes in care. The procedural burden must be weighed against risk and available alternatives.

Niacin can lower Lp(a), but it is not routinely used for this purpose because biomarker reduction has not produced a convincing additional clinical benefit in the settings studied and is associated with adverse effects. Hormone therapy is likewise not prescribed to treat elevated Lp(a). Aspirin in primary prevention does not automatically follow from the result: signals from subgroups or observational studies must be weighed against bleeding risk and do not amount to a universal indication. Anticoagulation requires separate indications.

Selective therapies mainly target apo(a) synthesis. Pelacarsen is an antisense oligonucleotide targeting LPA messenger RNA; olpasiran and lepodisiran use small interfering RNA with a prolonged effect. Published studies have shown large reductions in concentration, approaching almost complete suppression with some regimens. Placebo-adjusted percentages can mathematically appear to exceed 100% and do not mean that a biological concentration becomes negative.

The phase 2 trial of pelacarsen documented dose-dependent reduction; OCEAN(a)-DOSE demonstrated the lipid-lowering effect of olpasiran, and studies of lepodisiran characterized the duration of its effect. These findings establish that the pathway can be modified pharmacologically, but do not, by themselves, demonstrate prevention of myocardial infarction, death, or aortic stenosis. Local reactions, hepatic safety, and other events must be assessed within the individual programs and with adequate follow-up.

As of the update date, October 16, 2026, a National Lipid Association communication on preliminary Lp(a)HORIZON results reports that pelacarsen did not meet the primary cardiovascular endpoint despite lowering Lp(a). The communication explicitly distinguishes the announcement from the full results, which were not yet available in that document. These preliminary data must not be equated with a complete publication, nor do they permit definitive conclusions about all molecules, populations, or treatment durations.

Clinical interpretation must keep genetic causality, efficacy on the biomarker, and efficacy of a particular strategy on clinical events separate. A negative trial does not automatically invalidate all causal evidence, but it precludes promising a clinical benefit solely on the basis of the reduction achieved. Other programs are evaluating different molecules and populations; any future adoption must depend on relevant results, regulatory approvals, and indications, without presenting what remains under investigation as established.

In aortic stenosis, lowering Lp(a) alone has not been shown to replace surveillance or valvular intervention. LDL-lowering therapy remains indicated for atherosclerotic risk when appropriate, but it should not be described as a definitive treatment for established valvular calcification. New symptoms such as dyspnea, angina, or syncope require reassessment even if the lipid profile has improved.

Follow-up prioritizes adherence, attainment of modifiable targets, and recognition of symptoms. Repeating Lp(a) measurement may be useful when an intervention modifies it, when the clinical context changes, or in research, but there is no need to pursue minor fluctuations in a stable individual. Communication should make clear that “genetic” primarily means persistent predisposition, not an inability to reduce overall risk.

Prognosis and complications

Prognosis varies with concentration and baseline risk. Very high Lp(a) increases the lifetime likelihood of disease but does not make an event inevitable within a specific interval. In patients with established atherosclerosis, it may contribute to recurrent events despite controlled LDL; in young people, it provides a reason to avoid accumulating additional exposures. The benefits of available preventive measures remain relevant even when the particle itself is not directly normalized.

The best-documented complications include coronary artery disease, myocardial infarction, peripheral arterial disease, and calcific aortic stenosis; the association with stroke also depends on subtype and context. Not every cardiovascular event in a person with high Lp(a) is necessarily caused by it. Careful evaluation continues to consider atrial fibrillation, hypertension, smoking, and other relevant mechanisms, avoiding a single explanation that could obscure treatable causes.

The clinical value of recognizing elevation lies in earlier prevention, identification of affected relatives, and accurate interpretation of residual risk. Decisions must remain proportionate to the evidence: intensify control of modifiable factors, treat documented diseases, and reassess novel therapies when adequate clinical outcomes become available, without replacing probabilistic prognosis with a deterministic prediction.

References
  1. Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43(39):3925–3946.
  2. Koschinsky ML et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology. 2024;18(3):e308–e319.
  3. Mach F et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378.
  4. Blumenthal RS et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2026;87(19):2624–2757.
  5. Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42(34):3227–3337.
  6. Borén J et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2020;41(24):2313–2330.
  7. Langlois MR et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry. 2018;64(7):1006–1033.
  8. Thanassoulis G et al. Genetic Associations with Valvular Calcification and Aortic Stenosis. The New England Journal of Medicine. 2013;368(6):503–512.
  9. O’Donoghue ML et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483–1492.
  10. Tsimikas S et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. The New England Journal of Medicine. 2020;382(3):244–255.
  11. O’Donoghue ML et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. The New England Journal of Medicine. 2022;387(20):1855–1864.
  12. Nissen SE et al. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). The New England Journal of Medicine. 2025;392(17):1673–1683.
  13. National Lipid Association. Top Line Results from the Phase 3 Lp(a)HORIZON Trial. National Lipid Association, comunicazione istituzionale. 14 settembre 2026.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.